Bullzeye FinancialNATCO Pharma Ltd.
NSE: NATCOPHARM · Healthcare
Severe Q1 earnings collapse (−43% revenue, −57% profit) unattributed to specific cause, combined with weak technicals (price below all…
Capital raise is disciplined (₹750 pricing, 10.6% discount), dividend sustainability signals underlying cash resilience, and technical support at 52w low creates asymmetric risk/reward if turnaround executes within 2–3 quarters.
Q1 FY27 collapse (−43% revenue, −57% profit) is material and unattributed; capital raise during earnings crisis signals execution risk, and stock sits only 5.85% above 52w low in bearish EMA stack with low volume conviction.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bearish 28 Sep 2026 → now Scores 28 Oct 2026₹828.55 → ₹828.55 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →